Kymera Therapeutics Inc (NASDAQ: KYMR) is 60.33% higher on its value in year-to-date trading and has touched a low of $22.35 and a high of $53.27 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The KYMR stock was last observed hovering at around $40.79 in the last trading session, with the day’s gains setting it 0.03%.
Currently trading at $40.82, the stock is -6.69% and -10.79% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.11 million and changing 0.07% at the moment leaves the stock -1.17% off its SMA200. KYMR registered 58.83% gain for a year compared to 6-month gain of 36.57%. The firm has a 50-day simple moving average (SMA 50) of $45.8638 and a 200-day simple moving average (SMA200) of $41.31095.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -9.25% loss in the last 1 month and extending the period to 3 months gives it a -21.39%, and is -3.50% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.28% over the week and 5.67% over the month.
Kymera Therapeutics Inc (KYMR) has around 187 employees, a market worth around $2.65B and $87.56M in sales. Profit margin for the company is -191.26%. Distance from 52-week low is 82.64% and -23.37% from its 52-week high. The company has generated returns on investments over the last 12 months (-17.30%).
with sales reaching $14.81M over the same period.The EPS is expected to shrink by -11.96% this year, but quarterly earnings will post -31.49% year-over-year. Quarterly sales are estimated to shrink -69.06% in year-over-year returns.
Kymera Therapeutics Inc (KYMR) Top Institutional Holders
261.0 institutions hold shares in Kymera Therapeutics Inc (KYMR), with institutional investors hold 109.79% of the company’s shares. The shares outstanding are 64.75M, and float is at 55.01M with Short Float at 15.99%. Institutions hold 108.39% of the Float.
The top institutional shareholder in the company is PRICE T ROWE ASSOCIATES INC /MD/ with over 6.39 million shares valued at $190.76 million. The investor’s holdings represent 9.0301% of the KYMR Shares outstanding. As of 2024-06-30, the second largest holder is BAKER BROS. ADVISORS LP with 6.0 million shares valued at $178.98 million to account for 8.4724 of the shares outstanding. The other top investors are ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC which holds 5.35 million shares representing 7.5603% and valued at over $159.71 million, while BVF INC/IL holds 7.2937 of the shares totaling 5.16 million with a market value of $154.08 million.
Kymera Therapeutics Inc (KYMR) Insider Activity
The most recent transaction is an insider sale by Esposito Pamela, the company’s Director. SEC filings show that Esposito Pamela sold 2,500 shares of the company’s common stock on Dec 02 ’24 at a price of $49.00 per share for a total of $0.12 million. Following the sale, the insider now owns 0.0 shares.
Still, SEC filings show that on Sep 17 ’24, Esposito Pamela (Director) disposed off 13,500 shares at an average price of $48.28 for $0.65 million. The insider now directly holds 0 shares of Kymera Therapeutics Inc (KYMR).
